MDxHealth is a commercial-stage precision diagnostics company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of prostate cancer and other urologic diseases. The Company’s tests are based on proprietary genetic, epigenetic and other complex molecular technologies.
MDxHealth is dedicated to providing highly accurate and clinically actionable urologic solutions to inform patient diagnosis and treatment while improving healthcare economics for payers and providers.
An overview of the most recent information about MDxHealth can be found in the company’s periodic corporate presentation slides and can be download here. Corporate Presentation 2021
MDxHealth is listed on the Euronext and on NASDAQ under the ticker symbol MDXH.
MDxHealth has been listed on Euronext since 2006 and on NASDAQ since 2021. There is only one class of shares in the company (common shares) and all shares have the same rights and voting representation. Other than American Depository Shares (ADS) listed on NASDAQ (each representing ten common shares) and stock options issued to employees, directors, and some consultants, there are no other financial instruments issued by the company.
Corporate Governance Charter
MDxHealth attaches great value to corporate governance practices. On April 14, 2021, our board of directors approved the current version of MDxHealth’s Corporate Governance Charter. The Charter has been drafted in accordance with the principles of Belgian. Code on Corporate Governance.
The full text of MDxHealth’s Corporate Governance Charter can be download here: English
Code of Ethics
The full text of MDxHealth’s Code of Ethics can be downloaded here: English
As a listed company, MDxHealth must comply with rules governing insider trading. The company’s dealing code can be found here: English
Share capital history
The history of the share capital issuance since the inception of the company can be found here:
Transparency Declarations of the largest shareholders
The table below provides an overview of the shareholders that filed a notification with MDxHealth SA pursuant to applicable transparency disclosure rules. Although the applicable transparency disclosure rules require that a disclosure must be made by each person passing or falling under one of the relevant thresholds, it is possible that the information below in relation to a shareholder is no longer up-to-date. The percentages of voting rights mentioned in the table have been calculated on the basis of the currently outstanding shares.
|SHAREHOLDER (OR PARTY REPRESENTING SHAREHOLDERS)||MVM PARTNERS LLP||BLEICHROEDER LP||BIOVEST NV||VALIANCE ASSET MANAGEMENT||SCORPIAUX BVBA|
|% OF OUTSTANDING SHARES||22.23%||15.25%||9.36%||12.30%||4.26%|
|SITUATION AS OF||May 15, 2020||Nov.19, 2021||Jan. 26, 2021||May 15, 2020||May 15, 2020|
|NOTIFICATION RECEIVED||May 18, 2020||Nov. 22, 2021||Feb. 1, 2021||May 21, 2020||June 2, 2020|
|NOTIFICATION FORM||Click here to view form||Click here to view form||Click here to view form||Click here to view form||Click here to view form|
*Percentage calculated as per the date of the relevant transaction and taking into account the total number of outstanding shares as per such date
Each natural or legal person acquiring or transferring MDxHealth’s shares is required to notify MDxHealth and the Financial Services and Markets Authority (FSMA) each time their shareholding crosses a threshold of three percent (3%) of the total number of outstanding shares (the denominator). Such notification is also required each time, as a result of an acquisition or transfer a threshold of five percent (5%) and a multiple of five percent (5%) is crossed. Complete information regarding this requirement is found in Article 14 of MDxHealth’s articles of association.
The transparency notifications should be reported within 5 business days of crossing the threshold by following the procedures outlined on the FSMA website found here.